Literature DB >> 20558556

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.

Adaani E Frost1, David B Badesch, Robyn J Barst, Raymond L Benza, C Gregory Elliott, Harrison W Farber, Abby Krichman, Theodore G Liou, Gary E Raskob, Prieya Wason, Kathleen Feldkircher, Michelle Turner, Michael D McGoon.   

Abstract

BACKGROUND: REVEAL (The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) provides current demographics of patients with group 1 pulmonary arterial hypertension (PAH) in the United States.
METHODS: A total of 2,967 patients with PAH diagnosed based on right-sided heart catheterization were enrolled in REVEAL between March 2006 and September 2007. Demographics from the REVEAL patient cohort and REVEAL subpopulations (matched by inclusion criteria to other registries) were compared with historic US registry data and other contemporary US and non-US national PAH registries by inclusion criteria, including the National Institutes of Health (NIH) PAH registry and the French PAH registry.
RESULTS: REVEAL patients matched to NIH registry patients were older at diagnosis (mean ± SE, 44.9 ± 0.6 years vs 36.4 ± 1.1 years; difference, 8.5 ± 1.4; P < .001) and more likely to be women (78.7 ± 1.2% vs 63.1 ± 3.5%; P < .001). REVEAL patients matched to French registry patients had similar age and severity at diagnosis, but REVEAL patients were more likely to be women (79.8 ± 0.8% vs 65.3 ± 1.8%; P < .001) and obese (BMI, ≥ 30 kg/m(2), 32.5 ± 1.0% vs 14.8 ± 1.4%; P < .001), whereas French patients were more likely to have HIV-associated PAH (6.2% vs 2.3%). The female preponderance is similar to that in other US-based contemporary registries.
CONCLUSIONS: At diagnosis, REVEAL patients were older than NIH registry patients and similar in age to patients enrolled in contemporary registries. Compared with NIH and contemporary European and UK registries, there was a striking preponderance of women, and REVEAL patients were more likely to be obese. These observations and the difference in HIV-associated PAH between REVEAL and other non-US contemporary registries warrant further investigation. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00370214; URL: clinicaltrials.gov.

Entities:  

Mesh:

Year:  2010        PMID: 20558556     DOI: 10.1378/chest.10-0075

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  105 in total

Review 1.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

2.  Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey.

Authors:  Charles D Burger; Aimee J Foreman; Dave P Miller; Robert E Safford; Michael D McGoon; David B Badesch
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

Review 3.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 4.  Novel approaches to pulmonary arterial hypertension drug discovery.

Authors:  Yon K Sung; Ke Yuan; Vinicio A de Jesus Perez
Journal:  Expert Opin Drug Discov       Date:  2016-02-27       Impact factor: 6.098

5.  Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Diana Khaybullina; Ami Patel; Tina Zerilli
Journal:  P T       Date:  2014-11

6.  Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?

Authors:  Andrew Van Tosh; Kenneth J Nichols
Journal:  J Nucl Cardiol       Date:  2018-06       Impact factor: 5.952

7.  More on idiopathic pulmonary arterial hypertension with a low diffusing capacity.

Authors:  Karen M Olsson; Jan Fuge; Katrin Meyer; Tobias Welte; Marius M Hoeper
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

8.  Safety of regadenoson stress testing in patients with pulmonary hypertension.

Authors:  Victor M Moles; Thomas Cascino; Ashraf Saleh; Krasimira Mikhova; John J Lazarus; Michael Ghannam; Hong J Yun; Matthew Konerman; Richard L Weinberg; Edward P Ficaro; James R Corbett; Vallerie V McLaughlin; Venkatesh L Murthy
Journal:  J Nucl Cardiol       Date:  2016-11-28       Impact factor: 5.952

9.  Pulmonary arterial hypertension in the elderly: Clinical perspectives.

Authors:  Nicholas Rothbard; Abhinav Agrawal; Conrad Fischer; Arunabh Talwar; Sonu Sahni
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

Review 10.  World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.

Authors:  Kurt W Prins; Thenappan Thenappan
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.